Nicotine therapeutic benefits: Difference between revisions

Line 1,392:

**Citation: Tizabi Y, Getachew B, Aschner M. Butyrate protects and synergizes with nicotine against iron- and manganese-induced toxicities in cell culture: Implications for neurodegenerative diseases. Res Sq [Preprint]. 2023 Oct 5:rs.3.rs-3389904. doi: 10.21203/rs.3.rs-3389904/v1. Update in: Neurotox Res. 2023 Dec 14;42(1):3. doi: 10.1007/s12640-023-00682-z. PMID: 37886507; PMCID: PMC10602090.

***Acknowledgement: Supported in part by: NIH/NIAAA R03 AA022479 and NIH/NIGMS (2 SO6 GM08016‐39) (YT), and NIEHS R01ES10563 and R01ES07331 (MA).

=== 2023: [https://pubmed.ncbi.nlm.nih.gov/36857384/ Parkinsonian phenotypes induced by Synphilin-1 expression are differentially contributed by serotonergic and dopaminergic circuits and suppressed by nicotine treatment.] ===

*Insect study

*We found that olfactory and visual symptoms are majorly contributed by the serotonergic system, and that motor symptoms and reduction in survival are mainly contributed by the dopaminergic system. Chronic nicotine treatment was able to suppress several of these symptoms. These results indicate that both the serotonergic and dopaminergic systems contribute to different aspects of PD symptomatology and that nicotine has beneficial effects on specific symptoms.

**Citation: Carvajal-Oliveros A, Dominguez-Baleón C, Sánchez-Díaz I, Zambrano-Tipan D, Hernández-Vargas R, Campusano JM, Narváez-Padilla V, Reynaud E. Parkinsonian phenotypes induced by Synphilin-1 expression are differentially contributed by serotonergic and dopaminergic circuits and suppressed by nicotine treatment. PLoS One. 2023 Mar 1;18(3):e0282348. doi: 10.1371/journal.pone.0282348. PMID: 36857384; PMCID: PMC9977059.

***Acknowledgement: This work was supported by the Consejo Nacional de Ciencia y Tecnología (CONACyT), grant number 255478 and by Dirección General de Asuntos del Personal Académico, Universidad Nacional Autónoma de México (DGAPA-PAPIIT) grant number IN206517) ER was the recipient of the grants. AC received fellowships (446128) from CONACYT, PAEP-UNAM and Alianza del Pacífico- AGCID. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

===2021 [https://www.nature.com/articles/s41598-021-88910-4 Nicotine suppresses Parkinson’s disease like phenotypes induced by Synphilin-1 overexpression in Drosophila melanogaster by increasing tyrosine hydroxylase and dopamine levels]===

@@ Line 1,392: / Line 1,392: @@
 **Citation: Tizabi Y, Getachew B, Aschner M. Butyrate protects and synergizes with nicotine against iron- and manganese-induced toxicities in cell culture: Implications for neurodegenerative diseases. Res Sq [Preprint]. 2023 Oct 5:rs.3.rs-3389904. doi: 10.21203/rs.3.rs-3389904/v1. Update in: Neurotox Res. 2023 Dec 14;42(1):3. doi: 10.1007/s12640-023-00682-z. PMID: 37886507; PMCID: PMC10602090.
 ***Acknowledgement: Supported in part by: NIH/NIAAA R03 AA022479 and NIH/NIGMS (2 SO6 GM08016‐39) (YT), and NIEHS R01ES10563 and R01ES07331 (MA).
+=== 2023: [https://pubmed.ncbi.nlm.nih.gov/36857384/ Parkinsonian phenotypes induced by Synphilin-1 expression are differentially contributed by serotonergic and dopaminergic circuits and suppressed by nicotine treatment.] ===
+*Insect study
+*We found that olfactory and visual symptoms are majorly contributed by the serotonergic system, and that motor symptoms and reduction in survival are mainly contributed by the dopaminergic system. Chronic nicotine treatment was able to suppress several of these symptoms. These results indicate that both the serotonergic and dopaminergic systems contribute to different aspects of PD symptomatology and that nicotine has beneficial effects on specific symptoms.
+**Citation: Carvajal-Oliveros A, Dominguez-Baleón C, Sánchez-Díaz I, Zambrano-Tipan D, Hernández-Vargas R, Campusano JM, Narváez-Padilla V, Reynaud E. Parkinsonian phenotypes induced by Synphilin-1 expression are differentially contributed by serotonergic and dopaminergic circuits and suppressed by nicotine treatment. PLoS One. 2023 Mar 1;18(3):e0282348. doi: 10.1371/journal.pone.0282348. PMID: 36857384; PMCID: PMC9977059.
+***Acknowledgement: This work was supported by the Consejo Nacional de Ciencia y Tecnología (CONACyT), grant number 255478 and by Dirección General de Asuntos del Personal Académico, Universidad Nacional Autónoma de México (DGAPA-PAPIIT) grant number IN206517) ER was the recipient of the grants. AC received fellowships (446128) from CONACYT, PAEP-UNAM and Alianza del Pacífico- AGCID. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
 ===2021 [https://www.nature.com/articles/s41598-021-88910-4 Nicotine suppresses Parkinson’s disease like phenotypes induced by Synphilin-1 overexpression in Drosophila melanogaster by increasing tyrosine hydroxylase and dopamine levels]===